There is a market potential for biosimilars by 2019 when 50% of the biologics market is forecast to belong to off-patent drugs as there is tremendous interest by big pharma and generics companies in biosimilars industry, according to the new Global & USA Biosimilar Market Analysis to 2021 research report, available from ReportsnReports.com.
The USA, Europe and Japan are spending the most on biologics and therefore will become the largest biosimilar market hubs. Biosimilars generated revenues of $1.1 million in 2007 and gradually rose to $86.9 million in 2014. During this period, the market penetration of biosimilars in Europe and emerging markets was only about 8%. According to this new 2015 biosimilar market research, by 2019, 50% of the biologics market will belong to off-patent drugs, creating a high market potential for biosimilars. Globally, the biosimilars market is expected to expand at a compound annual growth rate of 22%.
Top-five biologicals generate annual sales of about $50 billion
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze